TY - JOUR
T1 - Modified T cells as therapeutic agents
AU - Singh, Nathan
N1 - Publisher Copyright:
© 2021 American Society of Hematology. All rights reserved.
PY - 2021/12/10
Y1 - 2021/12/10
N2 - Immunotherapy is now a well-established modality in the treatment of cancer. Although several platforms to redirect the immune response exist, the use of genetically modified T cells has garnered particular attention in recent years. This is due, in large part, to their success in the treatment of B-cell malignancies. Adoptively transferred T cells have also demonstrated efficacy in the treatment of systemic viral infections that occur following hematopoietic cell transplantation prior to immune reconstitution. Here we discuss the techniques that enable redirection of T lymphocytes to treat cancer or infection and the current indications for these therapies.
AB - Immunotherapy is now a well-established modality in the treatment of cancer. Although several platforms to redirect the immune response exist, the use of genetically modified T cells has garnered particular attention in recent years. This is due, in large part, to their success in the treatment of B-cell malignancies. Adoptively transferred T cells have also demonstrated efficacy in the treatment of systemic viral infections that occur following hematopoietic cell transplantation prior to immune reconstitution. Here we discuss the techniques that enable redirection of T lymphocytes to treat cancer or infection and the current indications for these therapies.
UR - http://www.scopus.com/inward/record.url?scp=85122153643&partnerID=8YFLogxK
U2 - 10.1182/hematology.2021000262
DO - 10.1182/hematology.2021000262
M3 - Article
C2 - 34889384
AN - SCOPUS:85122153643
SN - 1520-4391
VL - 2021
SP - 296
EP - 302
JO - Hematology (United States)
JF - Hematology (United States)
IS - 1
ER -